Biolinq Secures $58M Financing Led by Alpha Wave Ventures for Glucose Sensor Development

Biolinq Incorporated, a healthcare technology company based in San Diego, announced it has successfully raised $58 million in funding led by Alpha Wave Ventures, with participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors. The financing will support the completion of a U.S. pivotal clinical trial for Biolinq’s intradermal glucose sensor and the subsequent FDA submission.

The wearable patch uses electrochemical sensors to measure glucose levels from the intradermal space just beneath the skin’s surface. Rich Yang, CEO of Biolinq, highlighted their approach to accessing the skin for biosensing without the use of needles or bleeding. The wearable patch includes an intuitive display to inform users about glucose levels.